An Open-label, Multicenter Study to Assess the Safety of RO5185426 in Patients With Metastatic Melanoma

Trial Profile

An Open-label, Multicenter Study to Assess the Safety of RO5185426 in Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Registrational
  • Sponsors Roche
  • Most Recent Events

    • 04 Apr 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 01 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 01 Dec 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top